What does peripheral enhancement on MRI of a pancreatic neuroendocrine tumor liver metastasis treated with microwave (MW) ablation indicate, particularly when one lesion shows restricted diffusion and the other does not?

Peripheral Enhancement in Post-MW Ablation PNET Liver Metastases

Peripheral enhancement in a treated PNET liver metastasis following microwave ablation most likely represents residual viable tumor, particularly when accompanied by restricted diffusion, which strongly suggests active malignancy requiring additional treatment.

Understanding the Imaging Findings

The peripheral enhancement pattern you're observing reflects enhancement in compact tumor cells located at the periphery of the lesion 1. This finding has a 98% positive predictive value for malignancy in untreated metastases 1, and this principle extends to post-ablation scenarios where it indicates incomplete treatment.

Critical Distinction: The Lesion with Restricted Diffusion

The lesion showing both peripheral enhancement AND restricted diffusion is highly concerning for:

• Residual viable tumor with high cellularity
• Active malignancy requiring immediate intervention
• Incomplete ablation with persistent metabolically active disease

The restricted diffusion indicates densely packed viable tumor cells with restricted water molecule movement, a hallmark of active malignancy 2, 3.

The Lesion Without Restricted Diffusion

The lesion with peripheral enhancement but no restricted diffusion likely represents:

• Post-ablation inflammatory changes with perilesional enhancement
• Granulation tissue and vascular proliferation in compressed liver parenchyma
• Expected post-treatment changes that may resolve over time

This perilesional enhancement can occur from inflammatory cells and vascular proliferation in the compressed liver surrounding the ablation zone 1, 4.

Clinical Context for PNET Metastases

PNET liver metastases are characteristically hyperenhancing on arterial phase imaging, with the majority showing avid enhancement 1, 5, 1. After ablation:

• Normal post-ablation appearance: The ablation zone should show no enhancement centrally, with a thin smooth rim of perilesional enhancement that gradually decreases over time 4
• Abnormal findings: Nodular or irregular peripheral enhancement, especially with restricted diffusion, indicates treatment failure 4, 2

Recommended Management Algorithm

For the lesion with peripheral enhancement + restricted diffusion:

1. Immediate biopsy or repeat ablation should be strongly considered
2. Correlate with serum tumor markers if functional tumor
3. Consider functional imaging (Ga-68 DOTATATE PET/CT) for staging 6
4. Multidisciplinary team discussion for treatment planning 7, 8

For the lesion with peripheral enhancement alone:

1. Short-interval follow-up MRI at 1-3 months 4
2. Monitor for evolution of enhancement pattern
3. If enhancement persists or increases, consider biopsy or re-treatment
4. If enhancement decreases, continue surveillance

Key Imaging Pearls

• ADC values correlate inversely with tumor grade in PNET metastases; lower ADC suggests higher grade and more aggressive disease 3
• Arterial phase imaging is essential for PNET metastases, as these are hypervascular tumors 1, 5, 1
• Diffusion-weighted imaging should be part of every post-ablation surveillance protocol to detect early recurrence 9, 2

Common Pitfalls to Avoid

• Don't dismiss peripheral enhancement as benign in the early post-ablation period—it requires careful correlation with diffusion imaging and follow-up
• Don't wait too long to act on lesions with restricted diffusion; these represent viable tumor requiring prompt intervention
• Don't rely on enhancement patterns alone—always integrate diffusion imaging, size changes, and clinical context 4, 2

The combination of peripheral enhancement with restricted diffusion is a red flag for residual disease that warrants aggressive management, while peripheral enhancement alone may represent expected post-treatment changes requiring surveillance 4, 2, 10.